Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Makoto Chuma(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Hisashi Hidaka(Kitasato University), Satoshi Moriya(Yokohama City University Medical Center), Nobuhiro Hattori(St. Marianna University School of Medicine), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Yoshimasa Shimma(Tokai University), Shuichiro Iwasaki(Kitasato University), Yoshitaka Arase(Tokai University), Shun Tezuka(Kanagawa Prefectural Hospital Organization), Chika Kusano(Kitasato University), Naohisa Wada(Kitasato University), Kota Tsuruya(Tokai University), Shunji Hirose(Tokai University), Haruki Uojima(National Center for Global Health and Medicine), Tsunamasa Watanabe(St. Marianna University School of Medicine), Yuki Miura(Japanese Red Cross Hadano Hospital), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Hiroki Ikeda(St. Marianna University School of Medicine), Kousuke Kubota(Kitasato University), Tatehiro Kagawa(Tokai University), Chikako Tokoro, Shigeru Iwase(Fujisawa City Hospital), Takuya Ehira(St. Marianna University School of Medicine), Taito Fukushima(Kanagawa Prefectural Hospital Organization)
Hepatology Research
November 11, 2021
10.1111/hepr.13732
Cited by 50

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586